Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
作者信息
Willett Christopher G, Boucher Yves, Duda Dan G, di Tomaso Emmanuelle, Munn Lance L, Tong Ricky T, Kozin Sergey V, Petit Lucine, Jain Rakesh K, Chung Daniel C, Sahani Dushyant V, Kalva Sanjeeva P, Cohen Kenneth S, Scadden David T, Fischman Alan J, Clark Jeffrey W, Ryan David P, Zhu Andrew X, Blaszkowsky Lawrence S, Shellito Paul C, Mino-Kenudson Mari, Lauwers Gregory Y
出版信息
J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635.
PMID:16258121
Abstract
摘要
Zotero 插件